Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
40,7 USD | +0,05% |
|
-6,24% | +0,02% |
Vakgebied
Aantal werknemers: 2 200
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Rubenstein
FOU | Founder | 74 | 01-01-87 |
William Conway
FOU | Founder | 74 | 01-01-87 |
Harvey Schwartz
CEO | Chief Executive Officer | 60 | 15-02-23 |
John Redett
DFI | Director of Finance/CFO | 56 | 01-01-07 |
Ruulke Bagijn
CIO | Chief Investment Officer | - | 01-05-19 |
Lúcia Soares
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-19 |
Bethany de Lude
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-21 |
Christopher Finn
COO | Chief Operating Officer | 66 | 01-03-19 |
Catherine Ziobro
CMP | Compliance Officer | - | 01-01-04 |
Jason Thomas
CTO | Chief Tech/Sci/R&D Officer | - | 01-12-10 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
William Shaw
BRD | Director/Board Member | 78 | 02-05-12 |
Lawton Fitt
BRD | Director/Board Member | 70 | 02-05-12 |
Linda Filler
BRD | Director/Board Member | 64 | 01-04-22 |
Derica Rice
BRD | Director/Board Member | 59 | 08-03-21 |
Anthony Welters
BRD | Director/Board Member | 69 | 27-10-15 |
James Hance
BRD | Director/Board Member | 79 | 01-11-05 |
William Conway
FOU | Founder | 74 | 01-01-87 |
David Rubenstein
FOU | Founder | 74 | 01-01-87 |
Daniel D'Aniello
FOU | Founder | 77 | 01-01-87 |
Harvey Schwartz
CEO | Chief Executive Officer | 60 | 15-02-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 359 880 497 | 260 601 988 ( 72,41 %) | 0 | 72,41 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
ADICON HOLDINGS LIMITED 38.71% | 281 541 805 | 38.71% | 294 377 296 $ |
SAKATA INX CORPORATION 0.41% | 221 000 | 0.41% | 2 683 305 $ |
HOKUETSU CORPORATION 0.16% | 293 449 | 0.16% | 2 283 802 $ |
RENGO CO., LTD. 0.08% | 209 608 | 0.08% | 1 413 215 $ |
NAGASE & CO., LTD. 0.04% | 51 000 | 0.04% | 998 613 $ |
TSA SAS 0.95% | 4 678 140 | 0.95% | 685 628 $ |
ARTIENCE CO., LTD. 0.06% | 31 748 | 0.06% | 679 831 $ |
193 195 | 4.11% | 309 112 $ | |
49 461 | 0.04% | 305 305 $ | |
DAIO PAPER CORPORATION 0.03% | 44 227 | 0.03% | 249 131 $ |
Bedrijfsgegevens
The Carlyle Group, Inc.
1001 Pennsylvania Avenue NW
20004-2505, Washington
+202 729 5626
http://www.carlyle.com![Adres The Carlyle Group Inc.(CG)](https://cdn.zonebourse.com/static/address/10531255.png)
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Abingworth Bioventures V LP
|
Investment Managers
|
Carlyle Investment Management LLC
![]() Carlyle Investment Management LLC Investment ManagersFinance Carlyle Investment Management LLC provides investment advisory services. It provides retail insurance and investment services across the US. The company's life insurance products include universal life insurance, term life coverage, and variable annuities. It was founded in 2007 and is located in Washington, DC. |
Investment Managers
|
Abingworth Clinical Co-Development Fund 2 LP
![]() Abingworth Clinical Co-Development Fund 2 LP Investment ManagersFinance Abingworth Clinical Co-Development Fund 2 LP is a private company based in London, UK. The British company was founded in 2020. |
Investment Managers
|
Abingworth Bioventures V Co-Invest Growth Equity Fund LP
|
Investment Managers
|
ABV 8 Strategic UK LP
|
Miscellaneous
|
Abingworth LLP
![]() Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. |
Investment Managers
|
Abingworth Bioventures 8 LP
![]() Abingworth Bioventures 8 LP Investment ManagersFinance Abingworth Bioventures 8 LP invests in private and public companies located across the UK, Europe and the US. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics and instrumentation. It provides financing for seed, early and later-stage capital requirements with an investment size ranging from $15 million to $30 million. It also makes majority or minority investments. |
Investment Managers
|
Abingworth Bioventures VII LP
![]() Abingworth Bioventures VII LP Investment ManagersFinance Abingworth Bioventures VII LP invests in private and public companies located in the US and Europe. The fund targets companies operating in the fields of life sciences and healthcare sectors such as medical devices, instrumentation, biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. It provides financing for seed, early and later-stage capital requirements with an investment size of $15 - $30 million. It seeks majority or minority investments in the companies. |
Investment Managers
|
Abingworth Bioventures VI LP
![]() Abingworth Bioventures VI LP Investment ManagersFinance Abingworth Bioventures VI LP invests in private and public companies located the US and Europe. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. The fund provides financing for seed, early and late stage capital requirements with an investment size of $15 - $30 million. It seeks Majority or minority investments in the companies. |
Investment Managers
|
Sector
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,02% | 14,64 mld. | |
+31,50% | 86,96 mld. | |
+15,07% | 25,88 mld. | |
-2,03% | 18,75 mld. | |
+4,87% | 14,5 mld. | |
-23,30% | 12,04 mld. | |
+18,28% | 9,77 mld. | |
+16,64% | 8,69 mld. | |
+24,85% | 7,08 mld. | |
+46,32% | 6,38 mld. |